- 견적 및 주문
- 제품/실험 Q&A
LentiBOOST는 세포독성이 없는 non-cytotoxic transduction enhancer로, 유전자세포치료제의 연구개발을 위한 전임상 및 임상연구에 매우 효과적으로 사용되고 있습니다.
Drug Development에 적용시 다음과 같은 benefit이 있습니다.
|SIRION Biotech licenses its LentiBOOST® transduction technology to Cellectis NEW
Munich, Germany and Cambridge, Mass., January 7, 2021– Through this license agreement, SIRION Biotech GmbH (“SIRION”) granted Cellectis non-exclusive right under its proprietary lentiviral transduction enhancer LentiBOOST®. This product complements Cellectis’...
Mustang Bio licenses LentiBOOST™ Technology from SIRION Biotech for the development of MB-207 lentiviral gene therapy
October 06, 2020 08:00 ET | Source: Mustang Bio, Inc., globenewswire.com WORCESTER, Mass. and MARTINSRIED, Germany, Oct. 06, 2020 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO) and SIRION Biotech GmbH (“SIRION”) today announced a licensing...
SIRION LentiBOOST™ transduction enhancer featured in Gene Therapy – Nature
Published on 27 April 2020 in Gene Therapy – Nature, the study titled “Optimizing lentiviral vector transduction of hematopoietic stem cells for gene therapy” was performed by the group of authors from St. Jude Children’s Research Hospital, Memphis, USA and Center for...
Beam Therapeutics Licenses SIRION Biotech’s LentiBOOST™ Technology for its CAR-T pipeline
April 07, 2020, MARTINSRIED, Germany–(BUSINESS WIRE)–SIRION Biotech GmbH announced today that Beam Therapeutics licensed rights to use SIRION Biotech’s LentiBOOST™ for use in their CAR-T cell products. LentiBOOST™ was engineered to improve lentiviral...
COPYRIGHT(c) 2008. 고마바이오텍(주). ALL RIGHTS RESERVED. Contact Webmaster for more information.
개인정보취급방침 (07207) 서울시 영등포구 양평로 21길 26 선유도역1차 아이에스비즈타워 19층 | TEL 02)579-8787 | FAX 02)578-7042.